Top 10 Books about Stock Investing to read in 2018. Read more.

IMUC - ImmunoCellular Therapeutics Ltd

Industry: Biotechnology Sector: Healthcare

IMUC - ImmunoCellular Therapeutics Ltd

Industry: Biotechnology Sector: Healthcare
#1760()/6711

Fri 23'rd Feb 2018

PERIOD 2017-11-24 - 2018-02-23
CHANGE 1.96%
PRICE $0.27
VOLUME
Sell
TREND
Sell

MV LONG
Sell

MV SHORT
Buy

PIVOT
Buy

MACD
Buy

Request Prediction
0.00%
Predict

ImmunoCellular Therapeutics Ltd Stock Analysis

Technical stock analysis for Fri 23'rd Feb 2018

Shorts 1.96% ( 2018-01-31 )
Cash n/a
Loans n/a
Beta 0.64
ROA -149.26
Buy candidate since 2018-02-22 Gain 1.96%

ImmunoCellular Therapeutics Ltd gained 1.96% in the last trading day, rising from $0.26 to $0.27 , and has now gained 6 days in a row. It is not often that stocks manage to gain so many days in a row, and falls for a day or two should be expected. The price has risen in 7 of the last 10 days and is up by 15.27% over the past 2 weeks. Volume fell in the last day by -1.17 million shares, and in total, 1.01 million shares bought and sold for approximately $268 029. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.

Access today's Top 5 Buy Candidates

Trend

ImmunoCellular Therapeutics Ltd lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.93% during the next 3 months and, with 90% probability hold a price between $0.14 and $0.29 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

A buy signal was issued from a pivot bottom point on Thursday February 15, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. ImmunoCellular Therapeutics Ltd holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.27. On a fall, the stock will find some support from the short-term average at $0.25. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 57 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

ImmunoCellular Therapeutics Ltd finds support from accumulated volume at $0.26. On the upside the stock meets some resistance from accumulated volume at $0.29, $0.31 and $0.33.

Support: $0.26 Price: $0.27 Resistance: $0.29

Risk

This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.01 between high and low, or 4.33%. For the last week the stock has had a daily average volatility of 7.36%.

Since the ImmunoCellular Therapeutics Ltd has been rising for 6 days in a row, the risk for the next couple of days has increased. We don't expect a major reaction as the stock is in very good shape technically, and therefore hold a positive evaluation despite the very short term risk.

Our recommended stoploss: $0.25 (-4.14%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from pivot bottom found 5 days ago.)

Overall risk:

Very Low Low Medium High Very High

Evaluation

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term.

Trade IMUC CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

Access these features

Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder
Ad-free browsing

Become a PRO Now
Help us IMPROVE our CHARTS HERE.

Last donation

Do you find our website useful too?
Help us improve by making a small donation or
Get PRO features

START FREE 5-DAY TRIAL